Schellenberg Wittmer advises Swisscanto on Piomic’s growth equity financing
Schellenberg Wittmer advised Swisscanto (CH) private Equity Switzerland Growth II L-QIF KmGK, the growth fund managed by Zürcher Kantonalbank’s asset management division, in connection with its role as lead investor for Piomic Medical, a Swiss start-up spun out of ETH Zurich and focused on deep tissue regeneration through physical stimulation therapies, which has raised USD 25 million in growth equity. Swisscanto (CH) led the financing round with a CHF 10 million commitment.
Legal advisers
The Schellenberg Wittmer team was led by Christoph Vonlanthen, partner. He was supported by Christophe Granata Goldman, Gregory Marcos and Sven Riva on corporate and M&A aspects, Stéphanie Chuffart-Finsterwald and Nathan Matantu on IP and life sciences matters, and Sara Rousselle-Ruffieux and Elio Correia Fonseca on employment issues.
